.jpg)
.jpg)
.jpg)
Roche to swell US footprint with sweeping $50B investment, furthering pharma's onshoring push
The Swiss pharma's sweeping $50 billion investment comes as the threat of U.S. tariffs on pharmaceuticals continues to loom over the biopharma industry.
The Swiss pharma's sweeping $50 billion investment comes as the threat of U.S. tariffs on pharmaceuticals continues to loom over the biopharma industry.
